Latest On Onconova Therapeutics, Inc (ONTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 02:59 EST | News | Onconova Therapeutics GAAP EPS of -$0.28 beats by $0.02, revenue of $0.06M misses by $0.02M | N/A |  |
| 2023-05-16 02:59 EST | News | Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-23 22:47 EST | News | Onconova, Pangea team up to find biomarkers for cancer drug rigosertib | N/A | |
| 2023-03-17 12:25 EST | News | Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-16 21:37 EST | News | Onconova Therapeutics GAAP EPS of -$0.91 misses by $0.63, revenue of $0.23M beats by $0.17M | N/A | |
About Onconova Therapeutics, Inc (ONTX):
Onconova Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. The company's product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. Onconova Therapeut read more...ics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
General
- Name Onconova Therapeutics, Inc
- Symbol ONTX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:15
- Last Split Date2018-09-26
- Fiscal Year EndDecember
- IPO Date2013-07-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.onconova.com
Valuation
- Trailing PE 0.83
- Price/Sales (Trailing 12 Mt.) 843.21
- Price/Book (Most Recent Quarter) 24.21
- Enterprise Value Revenue 1331.21
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.10
- Next Year EPS Estimate -$0.12
- Operating Margin -10819%
- Return on Assets -72%
- Return on Equity -283%
- Revenue 231000
- Earnings Per Share -$3.81
- Revenue Per Share $0
- Gross Profit 231000
- Quarterly Earnings Growth 90%
Highlights
- Market Capitalization 265.01 million
- EBITDA -20981000
- Analyst Target Price $2.1
- Book Value Per Share $0.03
Share Statistics
- Shares Outstanding 236.61 million
- Shares Float 173.72 million
- % Held by Insiders 56%
- % Held by Institutions 11.21%
- Shares Short 18.24 million
- Shares Short Prior Month 16.35 million
- Short Ratio 0.21
- Short % of Float 8%
- Short % of Shares Outstanding 8%
Technicals
- Beta 1.91
- 52 Week High $1.87
- 52 Week Low $0.19
- 50 Day Moving Average 1.13
- 200 Day Moving Average 0.56
Dividends
- Dividend Date 2018-09-26
- ExDividend Date N/A
- Dividend Yield 0%
Onconova Therapeutics, Inc (ONTX) Dividend Calendar:
ONTX's last dividend payment was made to shareholders on September 26, 2018.
Onconova Therapeutics, Inc (ONTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Onconova Therapeutics, Inc (ONTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Onconova Therapeutics, Inc (ONTX) Chart:
Onconova Therapeutics, Inc (ONTX) News:
Below you will find a list of latest news for Onconova Therapeutics, Inc (ONTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Onconova Therapeutics, Inc (ONTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ONTX Trades:
Onconova Therapeutics, Inc (ONTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-09 | 8-K (Current report) | |
| 2020-08-31 | 8-K (Current report) | |
| 2020-08-31 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-31 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-24 | 8-K (Current report) | |
| 2020-08-12 | 8-K (Current report) | |
| 2020-08-12 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-04 | 8-K (Current report) | |
| 2020-07-10 | 8-K (Current report) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | 4 (Statement of changes in beneficial ownership of securities) | |
Onconova Therapeutics, Inc (ONTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Onconova Therapeutics, Inc (ONTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 56%
Institutional Ownership: 1121%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-27 | Michael B Hoffman | Director | Sell | 1,876.00 | 0.27 | 510.08 | 0.00 | |
| 2020-08-27 | E Premkumar Reddy | Director | Sell | 527,863.00 | 0.27 | 143,948.24 | 16,683.00 | |
| 2020-08-27 | Michael B Hoffman | Director | Sell | 182,492.00 | 0.27 | 49,619.57 | 21,919.00 | |
| 2020-05-19 | JEROME GROOPMAN | Director | Buy | 10,000.00 | 0.36 | 3,626.00 | 10,001.00 | |
| 2020-05-19 | Mark Patrick Guerin | Chief Financial Officer | Buy | 21,000.00 | 0.36 | 7,560.00 | 108,844.00 | |
| 2020-05-19 | Steven M Fruchtman | President, Chief Executive Off | Buy | 26,800.00 | 0.37 | 9,857.04 | 176,226.00 | |
| 2020-05-19 | ABRAHAM N. OLER | SVP Corp Dev & Gen Counsel | Buy | 15,000.00 | 0.37 | 5,550.00 | 90,000.00 | |
| 2019-11-25 | Steven M Fruchtman | President, Chief Executive Off | Buy | 149,000.00 | 0.20 | 29,800.00 | 149,426.00 | |
| 2019-11-25 | JAMES J MARINO | Director | Buy | 150,000.00 | 0.20 | 30,000.00 | 166,942.00 | |
| 2019-11-25 | VIREN MEHTA | Director | Buy | 250,000.00 | 0.20 | 50,000.00 | 250,857.00 | |
| 2019-11-25 | E Premkumar Reddy | Director | Buy | 500,000.00 | 0.20 | 100,000.00 | 544,546.00 | |
| 2019-11-25 | ABRAHAM N. OLER | VP Corp Dev & Gen Counsel | Buy | 75,000.00 | 0.20 | 15,000.00 | 75,000.00 | |
| 2019-11-25 | Mark Patrick Guerin | Chief Financial Officer | Buy | 87,500.00 | 0.20 | 17,500.00 | 87,844.00 | |
| 2019-09-25 | JAMES J MARINO | Director | Buy | 7,260.00 | 1.60 | 11,616.00 | 16,942.00 | |
| 2019-09-24 | CAPITAL PARTNERS L P TYNDALL | 10% Share Holder | Sell | 16,700.00 | 1.19 | 19,873.00 | 616,389.00 | |
| 2019-09-23 | CAPITAL PARTNERS L P TYNDALL | 10% Share Holder | Sell | 37,242.00 | 1.23 | 45,967.80 | 633,089.00 | |
| 2019-09-23 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Sell | 0.00 | 816,702.00 | | ||
| 2019-09-23 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Sell | 10,249.00 | 1.27 | 13,016.23 | 816,702.00 | |
| 2019-09-20 | CAPITAL PARTNERS L P TYNDALL | 10% Share Holder | Sell | 75,119.00 | 1.62 | 121,429.86 | 670,331.00 | |
| 2019-09-18 | 683 Capital Management, LLC | Insider | Sell | 1,533.00 | 2.20 | 3,375.97 | 460,000.00 | |